Part 4/8:
Dr. Andrew Brooks, a principal researcher involved in the development, explained that the test detects higher concentrations of the virus directly from saliva, facilitating more accurate results. Importantly, the technology behind this test is easily scalable and has been implemented in New Jersey and New York, with manufacturing already capable of producing millions of tests. The widespread deployment of such tests could accelerate efforts to identify asymptomatic carriers, allowing for targeted quarantines and a quicker return to normalcy.